PBPierre Blier

Pierre Blier

*This is an algorithmically generated author record based on publicly available information.

Pierre Blier has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Serotonin 1A Receptor Activation and Hypothermia in Humans Lack of Evidence for a Presynaptic Mediation

    by Pierre Blier, Bernard Seletti, Francois Gilbert, Simon N Young, Chawki Benkelfat

    The hypothermia produced by 5-HT1A agonists had initially been claimed to be caused by the activation of cell body 5-HT1A autoreceptors resulting in decreased 5-HT transmission in laboratory animals. In order to address this issue in humans, 12 healthy volunteers underwent a dietary tryptophan depletion paradigm to decrease 5-HT availability, under double-blind conditions, during which body temperature was monitored following oral administration of the 5-HT1A agonist buspirone (30 mg). In addition, plasma prolactin and growth hormone evaluations, two responses that are mediated via the direct activation of postsynaptic 5-HT1A receptors, were determined. The hypothesis was that if responses are mediated by decreased transmission at postsynaptic 5-HT1A receptors, resulting from dampened 5-HT release as a consequence of 5-HT1A autoreceptors activation, then responses to the exogenous 5-HT1A agonist should be attenuated when 5-HT availability has been markedly decreased beforehand. Buspirone produced the same significant increase in prolactin and growth hormone in the tryptophan-depleted state as in the control condition. Similarly, the degree of hypothermia produced by buspirone was not significantly different in the two experimental conditions. In conclusion, these results strongly suggest that the hypothermia and the increases in prolactin and growth hormone produced by buspirone are attributable to the enhanced activation of postsynaptic 5-HT1A receptors, and not to a decrease in 5-HT transmission resulting from the activation of the 5-HT1A cell body autoreceptors on 5-HT neurons.


  • Open Access

    Response

    by Pierre Blier, Julie Turcotte, Chantal Hébert, Guy Debonnel

  • Toward Optimal Treatments for Major Depression

    by Pierre Blier, Herbert Ward

    The treatment of major depression remains problematic for several reasons. In particular, the therapeutic response to medications usually does not manifest itself until a week after administration has begun, and more than half the patients will not experience a full recovery with the first antidepressant drug administration. There are, however, some pharmacologic strategies that can accelerate antidepressant response. When facing a treatment-resistant depression, combination therapy offers a more time-efficient approach to achieve remission than drug substitution. These interventions have been devised on a better understanding of the basis for the therapeutic response obtained with the first- and second-generation antidepressants, and evidence derived from controlled clinical trials of their superior effectiveness is growing. The rationale for such approaches will be described in this article, as well as their advantages and potential inconveniences. Ongoing research in this field continues to fuel the development of novel, better-tolerated, and more effective pharmacotherapies for depression.


  • Serotonin 1A receptor ligands act on norepinephrine neuron firing through excitatory amino acid and GABAA receptors: A microiontophoretic study in the rat locus coeruleus

    by Steven T. Szabo, Pierre Blier

    It was previously shown that the excitatory effect of the 5‐HT1A agonist 8‐OH‐DPAT on firing activity of locus coeruleus (LC) norepinephrine (NE) neurons and the inhibitory action of the 5‐HT1A antagonist WAY 100,635 are dependent on the presence of 5‐HT neurons, whereas the inhibitory action of the 5‐HT2 agonist DOI is not. Using in vivo extracellular unitary recordings performed in anesthetized rats, iontophoretic applications of the excitatory amino acid antagonist kynurenate attenuated the enhancement in firing produced by glutamate and kainate. In contrast, GABA applications decreased the firing activity of NE neurons which was attenuated by the enhancement produced by glutamate and kainate. In contrast, GABA applications decreased the firing activity of NE neurons which was attenuated by the GABAA receptor antagonist bicuculline. 8‐OH‐DPAT (10–60 μg kg−1, i.v.) produced a dose‐dependent enhancement in the firing activity of NE neurons that was abolished in the presence of kynurenate application. The selective 5‐HT1A receptor antagonist WAY 100,635 (100 μg kg−1, i.v.) suppressed NE firing which was reversed by the selective 5‐HT2A antagonist MDL 100,907 (200 μg kg−1, i.v.). In the presence of bicuculline, the inhibitory effect of WAY 100,635 was blunted. These results suggest that WAY 100,635 mainly attenuates NE neuron firing by blocking inhibitory 5‐HT1A receptors on glutamatergic neurons, thereby enhancing glutamate release and activating excitatory amino acid receptors, possibly of the kainate subtype, on 5‐HT terminals. The ensuing increased 5‐HT release would then act on excitatory 5‐HT2A receptors on GABA neurons that would ultimately mediate the inhibition of NE neurons. The prevention of the excitatory action of 8‐OH‐DPAT on NE neuron firing by kynurenate is also consistent with this neurocircuitry. Synapse 42:203–212, 2001.


  • Response of the Norepinephrine System to Antidepressant Drugs

    by Steven T. Szabo, Pierre Blier

    Environmental stimuli and drugs affect the norepinephrine (NE) system and may be linked to the manifestation and treatment of anxiety and affective disorders. The activity of locus ceruleus NE neurons in the brainstem can alter the function offorebrain structures associated with several psychiatric disorders. In particular, NE neurons send and receive projections from sensory afferents, limbic areas, and cortical areas implicated in higher-order brain malfunctions and the symptomatology of anxiety and affective disorders. In turn, anxiolytic and antidepressant drugs are able to offset perturbations of NE activity and forebrain structures with a time course congruent with their therapeutic action. All antide-pressants, even the agents selective for other biogenic amines or peptides, act on the NE system. In the present review, the effects of antidepressants on NE neurons are summarized and applied to the treatment of neuropsychiatric disorders, with emphasis placed on mechanisms of action.


  • Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons

    by Steven T. Szabo, Pierre Blier

    Reboxetine is a non‐tricyclic antidepressant with selective noradrenergic (NA) reuptake‐blocking effects. The effects of acute and sustained administration of reboxetine, on the firing activity of locus coeruleus NA neurons and dorsal raphe 5‐HT neurons, were assessed using in vivo extracellular unitary recording in rats anaesthetized with chloral hydrate. Reboxetine (0.1–1.25 mg/kg, i.v.) dose‐dependently decreased the firing activity of NA neurons (ED50 = 480 ± 14 µg/kg). A 2‐day treatment with reboxetine at 1.25, 2.5, 5, or 10 mg/kg per day (using osmotic minipumps implanted subcutaneously) produced significant decreases of 52%, 68%, 81%, and 83%, respectively, of NA firing activity. When the reboxetine treatment (2.5 mg/kg per day) duration was prolonged to 7 days, a 66% decrease in NA firing activity was observed which further decreased to 80% after 21 days of treatment. In contrast, 5‐HT neuron firing rate remained unaltered following short‐ and long‐term reboxetine treatments. The suppressant effect of the α2‐adrenoceptor agonist clonidine on the firing activity of NA neurons was unchanged in long‐term reboxetine‐treated rats, but its effect on the firing activity of 5‐HT neurons was blunted. The enhancement of NA firing activity by the 5‐HT1A agonist 8‐OH‐DPAT was abolished in long‐term reboxetine‐treated rats, whereas, the inhibitory effect of the 5‐HT2 agonist DOI was attenuated by about three‐fold. In conclusion, sustained NA reuptake blockade by reboxetine lead to profound alterations in the function of NA neurons and of 5‐HT receptors modulating their firing activity.


    • 1 January 2001
      • p. 12-7

    Pharmacology of rapid-onset antidepressant treatment strategies.

    by P Blier

    Although selective serotonin reuptake inhibitors (SSRIs) block serotonin (5-HT) reuptake rapidly, their therapeutic action is delayed. The increase in synaptic 5-HT activates feedback mechanisms mediated by 5-HT1A (cell body) and 5-HT1B (terminal) autoreceptors, which, respectively, reduce the firing in 5-HT neurons and decrease the amount of 5-HT released per action potential resulting in attenuated 5-HT neurotransmission. Long-term treatment desensitizes the inhibitory 5-HT1 autoreceptors, and 5-HT neurotransmission is enhanced. The time course of these events is similar to the delay of clinical action. The addition of pindolol, which blocks 5-HT1A receptors, to SSRI treatment decouples the feedback inhibition of 5-HT neuron firing and accelerates and enhances the antidepressant response. The neuronal circuitry of the 5-HT and norepinephrine (NE) systems and their connections to forebrain areas believed to be involved in depression has been dissected. The firing of 5-HT neurons in the raphe nuclei is driven, at least partly, by alpha1-adrenoceptor-mediated excitatory inputs from NE neurons. Inhibitory alpha2-adrenoceptors on the NE neuroterminals form part of a feedback control mechanism. Mirtazapine, an antagonist at alpha2-adrenoceptors, does not enhance 5-HT neurotransmission directly but disinhibits the NE activation of 5-HT neurons and thereby increases 5-HT neurotransmission by a mechanism that does not require a time-dependent desensitization of receptors. These neurobiological phenomena may underlie the apparently faster onset of action of mirtazapine compared with the SSRIs.